Concepedia

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

Fotios Polydoros, Jane F. Apperley, Dragana Milojković, Katherine A. Rothwell, Christopher Pocock, Hugues de Lavallade, Wendy Osborne, Lisa Robinson, Stephen G. O’Brien, Lucy Read,

The Lancet Haematology · 2019 · 195 citations · 18 references

DOI

Concepts

References

18

Prognostic discrimination in "good-risk" chronic granulocytic leukemia

JE Sokal, Cox Eb, Michele Baccarani et al. · Blood · 1984 · 1K citations · Full text

, , +13

Prognostic discrimination in "good-risk" chronic granulocytic leukemia

JE Sokal, Cox Eb, Michele Baccarani et al. · Blood · 1984 · 962 citations

, , +13

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

Hannah Bower, Magnus Björkholm, Paul W. Dickman et al. · Journal of Clinical Oncology · 2016 · 886 citations · Full text

, , +14

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 611 citations · Full text

, , +11

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

Joerg Hasford, Michele Baccarani, Verena Hoffmann et al. · Blood · 2011 · 497 citations · Full text

, , +13